ClinicalTrials.gg
CompletedNCT06431308Updated Oct 29, 2026

Nutritional Therapy to Incretin-based Anti-obesity Medications in the Management of Gastrointestinal Adverse Events

An interventional study of nutritional intervention in Obesity; Drug, sponsored by Ariel University. Completed at 3 sites in Israel. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Ariel University · Not applicable, Interventional, and Prevention

How we know

Updated Oct 29, 2026Now CompletedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 128 studies in Obesity with a site in Israel — 22 open to participants now, 29 under way, 16 of them phase 3. Obesity · Israel.

Enrollment
51st of 98
120 · median 128
Started
2025
with 7 others
No phase
55 of 128
7 open now
Registered
106th of 128
by date
Lead sponsor
3 of 128
Ariel University

Among the 128 studies in Obesity with a site in Israel, this one is the 51st largest by enrollment of the 98 interventional ones that give a count, is one of 8 that started in 2025, is one of 55 with no phase, and was the 106th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

22 of the 128 studies in Obesity with a site in Israel are open now. Recruiting first, the newest first:

17 more — sign in →

All 22 open studies →

A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 128 studies in Obesity with a site in Israel, or all of them as a file.
02

Study summary

The goal of the study is to evaluate the effect of nutrition intervention on gastrointestinal symptoms, treatment discontinuation rate, nutritional parameters (e.g., dietary intake and eating habits), anthropometric measures, functional parameters, and QOL during the initiation and up-titration phase of incretin-based Anti Obesity Medications (AOM) treatment in patients with overweight/obesity.

The nutrition intervention protocol will be developed based on literature review, focus groups with health care professionals, and patient interviews.

A single-center pilot study will be performed at the Tel-Aviv Assuta Medical Center, among 10 patients who are about to initiate long-term weight management treatment with Wegovy© (semaglutide 2.4 mg), followed by a multi-center, parallel design open-label, RCT, which will be conducted at the Tel-Aviv Assuta Medical Center and Rabin Medical Center - Beilinson Hospital, in 120 patients who are about to initiate long-term weight management treatment with Wegovy© or Mounjaro© .

The intervention group will receive nutrition guidance before AOM treatment by registered dietitian (RD) followed by nutrition and behavioral recommendations according to reported gastrointestinal symptom(s). The control group will receive the usual nutrition care for patients treated with AOM.

Primary outcomes (gastrointestinal symptom assessment) and secondary outcomes (incretin-based AOM discontinuation rate, nutritional parameters, anthropometrics, functional parameters and QOL) will be evaluated by interviews, questionnaires and measurements at baseline, at the end of Wegovy© or Mounjaro© titration phase [20 weeks (T1)] and weekly during the study period (for GI symptoms assessment).

03

Conditions studied

  • Obesity; Drug

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • individuals aged ≥ 18 years
  • eligible to receive AOM [i.e., ≥ 30 kg/m2 or ≥ 27 kg/m2 with at least one adiposity-related coexisting condition (e.g., diabetes or pre-diabetes, hypertension, dyslipidemia, obstructive sleep apnea, fatty liver, cardiovascular disease)]
  • who can read and speak Hebrew.

Exclusion criteria

Exclusion Criteria:

  • or precautious for treatment with Wegovy© or Mounjaro© [i.e., personal or family history of medullary thyroid cancer (MTC), personal history of multiple endocrine neoplasia type 2 (MEN2) syndrome, attempting conception, current pregnancy or breastfeeding]
  • previous bariatric surgery or endo-bariatric procedure
  • presence of chronic pancreatitis
  • treatment with AOM within a month before enrollment
  • patients with type 1 diabetes mellitus
  • patients who underwent other major GI surgery prior to medication treatment
  • patient with underlying GI disease [e.g., gastroparesis, celiac, Inflammatory Bowel Disease (IBD)]
  • a positive diagnosis of small-intestinal bacterial overgrowth (SIBO)
  • patients with active gastritis, gastroenteritis
  • chronic usage of promotility drugs or laxatives
  • patients with uncontrolled mental illness
  • significant cognitive deterioration
  • alcohol consumption exceeding 1 drink per day for women and 2 drinks per day for men .

In addition, participants who decide not to initiate or stop Wegovy© or Mounjaro© treatment for more than two consecutive injections for any reason or who undergo bariatric surgery or endoscopic sleeve gastroplasty during the study period will be excluded from the study

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    Nutritional intervention group

    Nutrition guidance before AOM treatment by registered dietitian (RD) followed by nutrition and behavioral recommendations according to reported gastrointestinal symptom(s).

    Behavioral: nutritional intervention

  • No intervention
    Control group

    * Usual nutrition care treatment for patients treated with Wegovy© or Mounjaro© (RCT). * Prior to the initiation of AOM treatment, participant will receive general nutrition guidance based on national recommendations according to the Mediterranean diet.

Interventions

  • Behavioralnutritional intervention

    A nutrition guidance before initiation of AOM treatment include recommendations for food choices and eating habits to minimize the occurrence and severity of GI symptoms during the up-titration phase, will be given by registered dietitian (RD) from the study team. Next, each week, participants will provide weekly reports of GI symptoms occurrence and severity, by responding to queries sent via WhatsApp/SMS and for occurring symptoms, an automatically structured nutrition and behavioral treatment recommendations will be sent . If participants expressed an interest in personalized dietary guidance on this matter, the study team RD will contact him/her by telephone, within a range of 48 hours, to provide individualized recommendations. Three days after each report of GI symptom(s), participants will receive an additional message and will be asked to report the occurrence and severity of the GI symptom, and their compliance with the specific dietary instructions received.

06

What researchers measure

Primary outcomes

  1. Gastrointestinal symptoms assessment

    GI symptoms rating scale (GSRS) - assess the degree of specific GI complaints Every question is rated by seven graded Likert-type scale (1 represents the absence of troublesome symptoms and 7 represents very troublesome symptoms) while a higher score of the whole questionnaire and by dimension represents more severe symptoms.

    Time frame: Baseline and at the end of the study period (20 weeks)

  2. Defecation texture

    Bristol stool scale - classifying the form of human feces into seven categories. Type 1-2 are considered abnormal hard stools and indicative of constipation type, and type 5-7 are considered abnormally loose/liquid stools and indicative of diarrhea or urgency

    Time frame: Baseline and at the end of the study period (20 weeks)

  3. Bowel Movement (BM) frequency

    will be assessed according to five acceptable categories: \>3 BMs/day, 2-3 BMs/day, 1-2 BMs/day, 3-4 BMs/week, \<3 BMs/week

    Time frame: Baseline and at the end of the study period (20 weeks)

  4. Participants gastrointestinal symptoms report

    Participant subjective and objective reporting of GI symptoms

    Time frame: Baseline, at the end of the study period (20 weeks) and weekly until 20 weeks (for subjective GI symptoms report only)

Secondary outcomes

  1. Incretin-based AOM treatment discontinuation rate

    Time frame: At the end of the study period (20 weeks) and weekly until 20 weeks

  2. Anthropometric measures - weight

    Weight (kg) by digital scale

    Time frame: Change from baseline at the end of the study period (20 weeks)

  3. Anthropometric measures - waist circumference (WC)

    will be measured by tape measure (cm)

    Time frame: Change from baseline at the end of the study period (20 weeks)

  4. Body composition - fat mass (kg)

    Body composition analysis using Inbody370S®

    Time frame: Change from baseline at the end of the study period (20 weeks)

  5. Dietary intake

    24-hour dietary recall (24HR)

    Time frame: Change from baseline at the end of the study period (20 weeks)

  6. Eating habits assessment

    General questions regarding eating patterns, hydration and foods intolerance

    Time frame: Change from baseline at the end of the study period (20 weeks)

  7. Eating habits assessment - Control of Eating

    Control of Eating Questionnaire (CoEQ) - The of CoEQ consists of 21 items (19 questions are rated by 100 mm VAS, and two question are open-ended). Greater score represents greater levels of Craving Control.

    Time frame: Change from baseline at the end of the study period (20 weeks)

  8. Functional parameters - muscle strength

    Handgrip (HG) muscle Strength - measure static muscle strength (kg) of the upper extremities by a digital hand dynamometer (Jamar plus digital©)

    Time frame: Change from baseline at the end of the study period (20 weeks)

  9. Functional parameters- leg strength and endurance

    30-seconds sit and stand test - counts the number of times the patient stands in 30 seconds. Higher scores means a better outcome.

    Time frame: Change from baseline at the end of the study period (20 weeks)

  10. Quality of life assessment

    EQ-5D-3L questionnaire -include the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS) .The EQ-5D-3L descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and extreme problems.The EQ VAS records the patient's self-rated health. Participants will be asked to subjectively rate their overall state of health by using a 0 to 100 VAS, with a higher score reflects a better outcome.

    Time frame: Change from baseline at the end of the study period (20 weeks)

  11. Eating habits assessment - Food preferences

    Leeds Food Preference Questionnaire (LFPQ). The questionnaire involves an explicit evaluation of "liking" and "wanting" for 16 food items that can be categorized as high-fat savory (HFSA), low-fat savory (LFSA), high-fat sweet (HFSW) and low-fat sweet (LFSW). Each food image is scored on a 100-mm VAS, while a higher score indicates a stronger preference for that food category. The second sub-task evaluates "implicit wanting" and requires rapid choice between 96 paired combinations of the food images from different categories

    Time frame: Change from baseline at the end of the study period (20 weeks)

  12. Anthropometric measures - height (cm)

    (cm) by altimeter

    Time frame: Change from baseline at the end of the study period (20 weeks)

  13. Body composition- percentage of body fat (BF%)

    Body composition analysis using Inbody370S®

    Time frame: Change from baseline at the end of the study period (20 weeks)

  14. Body composition - fat-free mass (kg)

    Body composition analysis using Inbody370S®

    Time frame: Change from baseline at the end of the study period (20 weeks)

  15. Body composition - skeletal muscle mass (kg)

    Body composition analysis using Inbody370S®

    Time frame: Change from baseline at the end of the study period (20 weeks)

Other outcomes

  1. Biochemical tests

    Participants will be asked to provide at T0 biochemical tests obtained during the last 3 months, including complete blood count, lipid profile, fasting glucose, HbA1c, iron, transferrin, ferritin, vitamin B12, folate, vitamin D, albumin and total protein

    Time frame: At baseline

  2. Demographics - age

    years

    Time frame: At baseline

  3. Demographics - marital status

    married, single, divorced or widowed

    Time frame: At baseline

  4. Demographics - education

    less than high school, high school graduate, high school diploma, bachelors degree, masters degree, MD or doctoral degree

    Time frame: At baseline

  5. Demographics - occupation status

    employee full time, employee part time, self-employed or other

    Time frame: At baseline

  6. Health status - Number of participants with coexisting medical conditions and their types

    T2DM, prediabetes, dyslipidemia, HTN,sleep apnea, orthopedic problems, GERD, mental disorder or other

    Time frame: Baseline and at the end of the study period (20 weeks)

  7. Number of participants using regular medications and their types

    usual medications

    Time frame: Baseline and at the end of the study period (20 weeks)

  8. Smoking habits

    smoker, former smoker or never

    Time frame: Baseline and at the end of the study period (20 weeks)

  9. Number of participants using supplementation and their Types

    multiviamin, Iron, vitamin D, folic acid, vitamin B12, calcium or other

    Time frame: Baseline and at the end of the study period (20 weeks)

  10. Lifestyle factors - Sleeping habits

    sleeping quality on a scale of 0-3 (0- very good, 1-quite good, 2- quite bad, 3- very bad)

    Time frame: Baseline and at the end of the study period (20 weeks)

  11. Lifestyle factors - frequency of physical activity

    number of exercises per week

    Time frame: Baseline and at the end of the study period (20 weeks)

  12. Lifestyle factors - duration of physical activity

    exercise time in minutes

    Time frame: Baseline and at the end of the study period (20 weeks)

  13. Lifestyle factors - type of physical activity

    aerobic or anaerobic

    Time frame: Baseline and at the end of the study period (20 weeks)

07

Study locations

3 sites
  • Assuta Medical Center
    Tel Aviv, Israel 6971028, Israel
  • Ariel University
    Ariel, 40700, Israel
  • Rabin Medical Center, Beilinson Hospital
    Petah Tikva, 4941492, Israel
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2025 to primary completion in Aug 2026, 18 months.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's 18 months is below that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: primary completion Feb 2026 → Aug 2026 and completion Mar 2026 → Aug 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2024
First posted
May 28, 2024
StartActual
Jan 30, 2025
Primary completionActual
Aug 5, 2026was Feb 2026
CompletionActual
Aug 5, 2026was Mar 2026
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 29, 2026
Sites
1 site added, 1 site removed
Show site
  • Assuta Medical Center · Tel Aviv, Israel
Show 1 removed
  • Assuta Medical Center · Tel Aviv, Israel
Oct 29, 2026
Primary completion
Feb 1, 2026→Aug 5, 2026 (actual)
Oct 29, 2026
Study completion
Mar 30, 2026→Aug 5, 2026 (actual)
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Recruiting→Completed
    1 site added, 1 site removed
    Show site
    • Assuta Medical Center · Tel Aviv, Israel
    Show 1 removed
    • Assuta Medical Center · Tel Aviv, Israel
    Primary completion Feb 1, 2026→Aug 5, 2026 (now actual)
    Study completion Mar 30, 2026→Aug 5, 2026 (now actual)
    + 3 other changes: verification date, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06431308
Lead sponsor
Ariel University
Responsible party
Shiri Sherf Dagan (Principal Investigator, Ariel University) — Principal investigator
First posted
May 28, 2024
Start date
Jan 30, 2025
Primary completion
Aug 5, 2026
Completion
Aug 5, 2026
Last update
Oct 29, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion